Brief: Esperion Therapeutics And Corstasis Therapeutics Announce Esperion’S Definitive Agreement To Acquire Corstasis, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)
03/03/2026 11:26
March 3 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION THERAPEUTICS AND CORSTASIS THERAPEUTICS ANNOUNCE ESPERION’S DEFINITIVE AGREEMENT TO ACQUIRE CORSTASIS, EXPANDING ITS CARDIOVASCULAR FRANCHISE WITH ENBUMYST™ (BUMETANIDE NASAL SPRAY) ESPERION THERAPEUTICS INC - DEAL INCLUDES $75 MILLION CASH PAYMENT AND $180 MILLION MILESTONE PAYMENTS ESPERION THERAPEUTICS INC - TO FINANCE ACQUISITION THROUGH CREDIT FACILITIES Source text: ID:nBw7XH1Tra Further company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi